Takeda Pharmaceutical (NYSE:TAK) Insider Giles Richard Platford Sells 55,617 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Platford sold 55,617 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $20.90, for a total transaction of $1,162,395.30. Following the completion of the sale, the insider owned 270,253 shares in the company, valued at $5,648,287.70. The trade was a 17.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Giles Richard Platford also recently made the following trade(s):

• On Monday, August 10th, Giles Platford sold 31,083 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30.

Takeda Pharmaceutical Stock Performance

NYSE TAK traded up $0.17 on Thursday, reaching $21.23. 4,438,160 shares of the company’s stock traded hands, compared to its average volume of 3,024,569. Takeda Pharmaceutical Co. has a fifty-two week low of $13.56 and a fifty-two week high of $21.73. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.60 and a current ratio of 1.15. The firm has a market cap of $68.05 billion, a price-to-earnings ratio of 27.94 and a beta of -0.02. The stock has a 50 day moving average price of $19.01 and a 200-day moving average price of $17.62.

Wall Street Analysts Forecast Growth

TAK has been the topic of a number of recent research reports. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 30th. Finally, Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Takeda Pharmaceutical has an average rating of “Buy”.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC lifted its holdings in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares during the period. Royal Bank of Canada grew its position in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after purchasing an additional 60,725 shares during the period. Ethic Inc. increased its stake in shares of Takeda Pharmaceutical by 19.5% during the third quarter. Ethic Inc. now owns 436,514 shares of the company’s stock worth $7,940,000 after purchasing an additional 71,261 shares in the last quarter. Finally, Bleakley Financial Group LLC increased its stake in shares of Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after purchasing an additional 68,844 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.